Home » Health » Clinical trial in China demonstrated that Sinovac vaccine is safe in children and adolescents

Clinical trial in China demonstrated that Sinovac vaccine is safe in children and adolescents

(EFE) – A new clinical trial developed in China, released today by The Lancet, suggests that the administration of two doses of the COVID-19 CoronaVac vaccine is safe in children and adolescents between 3 and 17 years and causes a strong immune response.

The proof, held among 550 minors, showed that more than 96% of those children and adolescents who received both injections of this preparation, manufactured by Sinovac, generated antibodies against SARS-CoV-2.

The study found that most adverse reactions were mild or moderate, and that the most common symptom reported by the participants was pain caused by the injection.

Read also: COVID-19: What you need to know about variants and mutations in the world

“Children and adolescents with COVID-19 usually develop mild or asymptomatic infections compared to adults; however, a small number could be at risk of severe disease, “says expert Qiang Gao, from Sinovac Life Sciences (China).

That expert indicates that minors “they can also transmit the virus to others, making it vital to test the safety and effectiveness of COVID-19 vaccines in younger age groups. “

“Our findings that CoronaVac was well tolerated and induced strong immune responses is very encouraging, and suggests that new studies in other regions, involving broader multiethnic populations, could provide valuable information to inform immunization strategies that involve children and adolescents, “he considered.

Read also: Minister Paris and modifications to the Step by Step plan: “We are going to take the time to do things right”

The first phase of the trial was carried out randomly in 72 healthy minors in Zanhuang (China) between October 31 and December 2, 2020.

The second phase was carried out between 480 participants between December 12 and 30 of that year.

The trial authors also admitted some “limitations” in their study, such as the fact that the response of the calls was not evaluated.s T cells, which play an important role in SARS-CoV-2 infections. They also noted that the aforementioned study involved a small number of participants, all of the same ethnicity, thus requiring larger trials in other regions with a variety of ethnicities.

In this way, the study recommends interpreting these results with caution, since it has not been possible draw solid statistical conclusions, according to their authors.

– .

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.